Join the PharmaShots Family of 20000+ Subscribers by PharmaShots

PharmaShots Feb 4, 2026

ZipBio and MeiraGTx Partner to Advance AAV Gene Therapy for Geographic Atrophy

Shots: Ref: PRnewswire | Image: ZipBio & MeiraGTx | Press Release Related News: Zonsen PepLib Biotech and Eli Lilly…

Read article →
PharmaShots Feb 4, 2026

ONWARD Medical First Patient in Empower BP Study of ARC-IM System to Treat Blood Pressure Instability in Spinal Cord Injury

Shots: Ref: Globenewswire | Image: ONWARD Medical | Press Release Related News: ONWARD Medical’s ARC-EX System…

Read article →
PharmaShots Feb 4, 2026

Relay Therapeutics’ Zovegalisib Receives the US FDA Breakthrough Therapy Designation for PIK3CA-Mutant Advanced Breast Cancer

Shots: Ref: Globenewswire | Image: Relay | Press Release Related News: BPGbio’s BPM31510 Receives the US FDA Orphan Drug…

Read article →
PharmaShots Feb 4, 2026

Pfizer Reports P-IIb (VESPER-3) Trial Results on PF’3944 in Weight Management

Shots: Ref: Pfizer | Image: Pfizer | Press Release Related News: Pfizer Signs ~$530M Deal to Use Novavax’s Adjuvant in…

Read article →
PharmaShots Feb 4, 2026

Quanterix Seeks US FDA Approval for Multi-Analyte Algorithmic Blood Test to Diagnose Alzheimer’s Disease

Shots: Ref: Businesswire | Image: Quanterix | Press Release Related News: Natera Seeks US FDA Approval for Signatera Cdx…

Read article →
PharmaShots Feb 4, 2026

Zonsen PepLib Biotech and Eli Lilly Partner to Advance Peptide-Based Therapies

Shots: Ref: Businesswire | Image: PepLib & Eli Lilly | Press Release Related News: Zonsen PepLib Biotech Grants Novartis…

Read article →
PharmaShots Feb 3, 2026

Key Biosimilars Events of January 2026   

Shots: Company: Samsung Bioepis Product: Byooviz Active Ingredient: Ranibizumab Reference Product: Lucentis Reference…

Read article →
PharmaShots Feb 3, 2026

Exelixis Reports the US FDA’s NDA Acceptance of Zanzalintinib + Tecentriq for Metastatic Colorectal Cancer (mCRC)

Shots: Ref: Exelixis | Image: Exelixis | Press Release Related News: Exelixis and Ipsen Report the EC’s Approval of…

Read article →